EU rejection of Kiadis's stem cell transplant adjunct means that two of three players in this space have been knocked back.
The group is desperately playing up mirvetuximab, but its future rests with a pair of earlier-stage projects.
A regulatory misstep puts Zogenix even further behind its epilepsy rival GW Pharma, which in turn is waiting for data that could give it another boost.
As the plot thickens around the trigger for Aveo’s equity raise, the EU regulator considers pulling the group's renal cancer drug from the market.
ALKS 5461 is headed back to the clinic or scrapheap, raising questions over whether Alkermes should remain in mental health drug development.
The FDA asks Amicus for more data on its Pompe disease candidate, but the company is already looking towards a Fabry disease gene therapy, and has made a remarkable…